Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAZ954 alone and with spartalizumab, NZV930, or NIR178 in advanced solid tumors
jRCT2080225114Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of kaz954, spartalizumab, NZV930 and taminadenant in Nonhematologic neoplasms (4 arms), sponsored by Novartis. Started Mar 2020; status: completed.
02
Drugs
kaz954spartalizumabNZV930taminadenant
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080225114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225114.